#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    T-cell type acute leukaemia Pyruvate kinase deficiency anaemia Osteopetrosis Liposarcoma Infantile apnoea Hypersensitivity pneumonitis Acute lymphocytic leukaemia recurrent Activated PI3 kinase delta syndrome Pancreatic carcinoma metastatic PIK3CA-activated mutation Marginal zone lymphoma refractory Pulmonary fibrosis Kidney transplant rejection Neuroblastoma recurrent Diffuse large B-cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Hepatoblastoma – Basic Information Prolymphocytic leukaemia – Diagnostics Andersen-Tawil syndrome – Life with Disease Pulmonary sarcoidosis Marfan’s syndrome – Treatment Combined immunodeficiency – Life with Disease Von Willebrand’s disease – Life with Disease Bronchopulmonary dysplasia – Basic Information Sarcoidosis – Basic Information Proteus syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PF-07868489 Leuprorelin Acetate Tofacitinib Chlorambucil Abc-23B-116 APAZUNERSEN Tasquinimod HUMAN COAGULATION FACTOR XIII Ion440 Anb032 Emicizumab Vobramitamab Duocarmazine Albaconazole BIIB115 Pelareorep Alrefimotide Glepaglutide Blu-263 Phosphate Levocabastine Hydrochloride Mecillinam More therapies…

    Learn about Your Condition

    Habitual abortion Hidradenitis Fragile X syndrome Bronchiectasis Head and neck cancer Interstitial lung disease Nasal sinus cancer Vitiligo Cholecystitis acute Pelvic venous thrombosis Reperfusion injury Acoustic neuroma Neuroendocrine carcinoma Fracture infection Diabetes insipidus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Exemestane
    • Tamoxifen Citrate
    Germany Greece Italy Spain

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Capecitabine
    • Datopotamab Deruxtecan
    Belgium France Germany Hungary Italy Poland +1

  • Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    Spain

  • Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Doxorubicin
    • Paclitaxel
    • Pembrolizumab
    Belgium France Germany Hungary Ireland Poland +2
Previous Page
1 … 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!